

RayBiotech, Inc.

3607 Parkway Lane suite 200 Norcross,GA 30092 Tel: 770-729-2992, 1-888-494-8555 Fax: 770-206-2393

Website: www.raybiotech.com Email: info@raybiotech.com

Certificate of Analysis and Data Sheet

Recombinant Human Osteoprotegerin, Fc Chimera

Catalog No. Source
228-11174 Pichia Pastoris.

Synonyms

TNFRSF11B, OPG, OCIF, Osteoclastogenesis inhibitory factor, TR1, MGC29565.

Introduction

Osteoprotegerin acts as decoy receptor for rankl and thereby neutralizes its function in osteoclastogenesis. OPG inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local rankl/opg ratio. Osteoprotegerin may also play a role in preventing arterial calcification. May act as decoy receptor for trail and protect against apoptosis. Trail binding blocks the inhibition of osteoclastogenesis.

Description

Recombinant OPG produced in yeast contains 412 amino acid residues, including 180 residues from mature OPG (a.a 22-201) and 232 residues from the Fc protein of human IgG1, and has a calculated molecular mass of 46.5 kDa. As a result of glycosylation, the recombinant Osteoprotegrin migrates as a 49 kDa protein in SDS-PAGE under reducing conditions.

The OPG is purified by proprietary chromatographic techniques.

Physical Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation

OPG was lyophilized from a 0.2μm filtered concentrated (0.5mg/ml) solution in PBS, pH= 7.4.

Purity

Greater than 90.0% as determined by:

- (a) Analysis by RP-HPLC.
- (b) Analysis by SDS-PAGE.

Solubility

It is recommended to reconstitute the lyophilized Osteoprotegerin in sterile $18M\Omega$ -cm H2O not less than $100\mu g/ml$, which can then be further diluted to other aqueous solutions.



RayBiotech, Inc.

3607 Parkway Lane suite 200 Norcross,GA 30092 Tel: 770-729-2992, 1-888-494-8555

Fax: 770-206-2393

Website: www.raybiotech.com Email: info@raybiotech.com

Amino Acid Sequence AA Sequence: OPG 22-201:

ETFPPKYLHYDEETSHQLLCDKCPPGTYLKQHCTAKWKTVCAPCPDHYY TDSWHTSDECLYCSPVCKELQYVKQECNRTHNRVCECKEGRYLEIEFCL KHRSCPPGFGVVQAGTPERNTVCKRCPDGFFSNETSSKAPCRKHTNCS VFGLLLTOKGNATHDNICSGNSESTOKCGIDVTL.

Fc232:

EPKSSDKTHTCPPCPAPEFEGAPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN GKEYKCKVSNKALPTPIEKTISKAKGQREPQVYTLPPSRDELTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK.

Biological Activity

Determined by its ability to neutralize the stimulation of U937 cells treated with 10ng/ml of soluble RANKL (sRANKL) corresponding to a Specific Activity of 100,000IU/mg.

Stability

Lyophilized Osteoprotegerin although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution OCIF should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).

Please prevent freeze-thaw cycles.